6 ML obiltoxaximab 100 MG/ML Injection — RxCUI 1746910
RxNorm drug concept · Semantic clinical drug
RxCUI 1746910
Semantic clinical drug · SCD
● Current RxNorm concept 1 FDA product
1 package NDC
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1746910
Official name6 ML obiltoxaximab 100 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asobiltoxaximab 600 MG per 6 ML Injection; obiltoxaximab 600 MG in 6 ML Injection
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
🕸️ Concept Web — How 6 ML obiltoxaximab 100 MG/ML Injection Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
6 ML obiltoxaximab 100 MG/ML Injection
RxCUI 1746910 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Obiltoxaximab
1746906IN
-
Obiltoxaximab
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Anthim
1746911BN
-
Anthim
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Obiltoxaximab Injection
1746909SCDF -
Obiltoxaximab Injectable Product
1746908SCDG -
Obiltoxaximab Injection [Anthim]
1746913SBDF -
Anthim Injectable Product
1746914SBDG -
Injection
1649574DF -
Injectable Product
1151126DFG
-
Obiltoxaximab Injection
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Obiltoxaximab 100 MG/ML
1746907SCDC -
6 ML obiltoxaximab 100 MG/ML Injection [Anthim]
1746915SBD -
Obiltoxaximab 100 MG/ML [Anthim]
1746912SBDC
-
Obiltoxaximab 100 MG/ML
Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Obiltoxaximab 100 MG/ML
SCDC · 1746907 -
Obiltoxaximab Injection
SCDF · 1746909 -
Obiltoxaximab Injectable Product
SCDG · 1746908
Brand-Name Concepts
-
6 ML obiltoxaximab 100 MG/ML Injection [Anthim]
SBD · 1746915 -
Obiltoxaximab 100 MG/ML [Anthim]
SBDC · 1746912 -
Obiltoxaximab Injection [Anthim]
SBDF · 1746913 -
Anthim Injectable Product
SBDG · 1746914 -
Anthim
BN · 1746911
📦 FDA Products & Package NDCs
1 product · 1 package NDC
1 package NDC map to RxCUI 1746910 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 69604-0204-02 | 1 VIAL, SINGLE-USE in 1 CARTON (69604-204-02) / 6 mL in 1 V... | Anthim | Elusys Therapeutics, Inc. | 2016-03-18 |
Observed labelers:
Elusys Therapeutics, Inc. (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.